Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop
Executive Summary
The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed
You may also be interested in...
Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting
Cancer Clinical Trial Sponsors Increasingly Favor Non-U.S. Sites, FDA Finds
The number of clinical trials used for registration of anticancer agents performed at least partially outside the U.S. has increased by approximately 50% in the last five years, FDA reported at the American Society of Clinical Oncology annual meeting
Cancer Drug Accelerated Approval Could Be Based On Pediatric Studies
Pharmaceutical companies could gain accelerated approval for oncologic agents based solely on pediatric testing of those drugs, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested